JPMorgan Lowers PT on Immunovant (IMVT) to $33 From $37

Immunovant, Inc. (NASDAQ:IMVT) is one of the best biotech stocks with high potential. On September 30, JPMorgan analyst Brian Cheng lowered the firm’s price target on Immunovant, Inc. (NASDAQ:IMVT) to $33 from $37 while keeping an Overweight rating on the shares.

Is Immunovant, Inc. (IMVT) The Most Undervalued Stock With Smart Money Ratings?

Immunovant, Inc. reported that its cash and cash equivalents totaled approximately $598.9 million in the quarter ending June 30, 2025, providing runway for announced indications through GD readout expected in 2027.

Immunovant, Inc. develops treatments for autoimmune diseases. Its product pipeline includes batoclimab and IMVT-1402. Both are novel antibodies targeting the neonatal fragment crystallizable receptor (FcRn).

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

This article is originally published at Insider Monkey.